摘要
钠-葡萄糖共转运蛋白2抑制剂(Sodium glucose co-transporter-2 inhibitors,SGLT-2i)是近年来上市的用于治疗2型糖尿病(Type 2 diabetes,T2DM)的一类新药。埃格列净是第4个批准上市的用于治疗T2DM的SGLT-2i。本文对该药的降糖机制、药动学、临床试验、药品不良反应等进行综述。
Sodium glucose co-transporter-2 inhibitor（ SGLT-2 i） is a newclass of drugs marketed in recent years for the treatment of type 2 diabetes. Ertugliflozin is the 4 th SGLT-2 i approved for the treatment of type 2 diabetes. This article reviews the hypoglycemic mechanism,pharmacokinetics,clinical trials,adverse drug reactions and other aspects of the drug.
作者
宋兆芮
陶娌娜
刘姝鑫
李艳娇
SONG Zhao-rui;TAO Li-na;LIU Shu-xin;LI Yan-jiao(College of Pharmacy,the First Hospital of Jilin University,Changchun 130021,China;Pharmaceutical Department,Jilin University,Changchun 130021,China)
出处
《实用药物与临床》
CAS
2018年第11期1309-1312,共4页
Practical Pharmacy and Clinical Remedies
